AUSTRALIAN medical device company Uscom has been approved for a new US Patent covering a non-invasive method of measuring suprasystolic blood pressure.
Founded by Rob Phillips and incorporated in 1999, Uscom’s key product is an ultrasonic cardiac output monitor which provides non-invasive, real time, and continuous measurement of cardiac output.
The newly approved patent covers a method central to the operations of its Uscom BP+ suprasystolic oscillometric blood pressure monitor.
Uscom took on the IP and manufacturing rights behind BP+ in June 2013, when it acquired all the assets of Pulsecor.
Executive Chairman of Uscom, Rob Phillips said that the patent is part of a suite of patents that will protect the BP+ technology commercially in the largest medical device market in the world.
“We are currently preparing to manufacture the Uscom BP+ and are actively establishing a new network of distribution into the specialized global BP markets,” Phillips said.
Unlike older devices that measure blood pressure in the arm or hand, the BP+ device measures the central blood pressure at the heart, using a non-invasive technology. The highly sensitive measurements provide a better insight into the health of the heart and blood vessels, with applications in managing hypertension.